Class i phosphoinositide 3-kinases in normal and pathologic hematopoietic cells

Current Topics in Microbiology and Immunology

Volumn 362, Issue , 2012, Pages 163-184

  Vergez, François ^a   Recher, Christian ^a   Payrastre, Bernard ^b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Acute myeloid leukemia; Hematopoiesis; Hematopoietic malignancies; Hematopoietic stem cells; Leukemic initiating cells; PI 3 kinases and phosphatases

Indexed keywords

MEMBRANE RECEPTOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; DEREGULATION; ENZYME ACTIVITY; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; MEGAKARYOCYTE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 84869996733     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-5025-8_8     Document Type: Article

References (112)

1. Aggerholm A, Gronbaek K, Guldberg P, Hokland P (2000) Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol 65:109-113 (Pubitemid 30615084)
2. Angeloni D, Danilkovitch-Miagkova A, Ivanova T, Braga E, Zabarovsky E, Lerman MI (2007) Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 26:4499-4512 (Pubitemid 47037040)
3. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T (2004) Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118:149-161 (Pubitemid 38962572)
4. Bai H, Xu R, Cao Z, Wei D, Wang C (2011) Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585:402-408
5. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B (2006) Key role of the p110delta isoform of PI3 K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107:642-650 (Pubitemid 43076389)
6. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, Khwaja A (2006) A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25:6648-6659 (Pubitemid 44646192)
7. Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A (2009) Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res 69:1027-1036
8. Bone HK, Welham MJ (2007) Phosphoinositide 3-kinase signalling regulates early development and developmental haemopoiesis. J Cell Sci 120:1752-1762 (Pubitemid 46930413)
9. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737 (Pubitemid 27298715)
10. Bouscary D, Pene F, Claessens YE, Muller O, Chretien S, Fontenay-Roupie M, Gisselbrecht S, Mayeux P, Lacombe C (2003) Critical role for PI 3-kinase in the control of erythropoietininduced erythroid progenitor proliferation. Blood 101:3436-3443 (Pubitemid 36857926)
11. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J, Buerger H, Muller-Tidow C, Choudhary C, McMahon M et al (2005) Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65:9643-9650 (Pubitemid 41541439)
12. Buitenhuis M, Verhagen LP, Van Deutekom HW, Castor A, Verploegen S, Koenderman L, Jacobsen SE, Coffer PJ (2008) Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 111:112-121
13. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106:1824-1830 (Pubitemid 41208600)
14. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, Seandel M, Shido K, White IA, Kobayashi M et al (2010) Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6:251-264
15. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR et al (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846 (Pubitemid 37351468)
16. Carlton JG, Cullen PJ (2005) Coincidence detection in phosphoinositide signaling. Trends Cell Biol 15:540-547 (Pubitemid 41398187)
17. Chabanon A, Desterke C, Rodenburger E, Clay D, Guerton B, Boutin L, Bennaceur-Griscelli A, Pierre-Louis O, Uzan G, Abecassis L et al (2008) A cross-talk between stromal cell-derived factor-1 and transforming growth factor-beta controls the quiescence/cycling switch of CD34 (+) progenitors through FoxO3 and mammalian target of rapamycin. Stem Cells 26:3150-3161
18. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F et al (2010a) Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3 K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95:415-423
19. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A et al (2010b) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16:5424-5435
20. Chetram MA, Don-Salu-Hewage AS, Hinton CV (2011) ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochem Biophys Res Commun 410:195-200
21. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, et al (2008) Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 1: ra3
22. Cornejo MG, Mabialah V, Sykes SM, Khandan T, Lo Celso C, Lopez CK, Rivera-Munoz P, Rameau P, Tothova Z, Aster JC et al (2011) Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood 118:1264-1273
23. Costa C, Hirsch E (2010) More than just kinases: the scaffolding function of PI3 K. Curr Top Microbiol Immunol 346:171-181
24. Di Paolo G, De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443:651-657 (Pubitemid 44564702)
25. Dick JE (2009) Looking ahead in cancer stem cell research. Nat Biotechnol 27:44-46
26. Doepfner KT, Spertini O, Arcaro A (2007) Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21:1921-1930 (Pubitemid 47299965)
27. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C (2008) A critical role for Lyn in acute myeloid leukemia. Blood 111:2269-2279 (Pubitemid 351451434)
28. Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Recher C (2012) The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia (in press)
29. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B (2010) Activity of any class IA PI3 K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 107:11381-11386
30. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Recher C (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23:1029-1038
31. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 104:7809-7814 (Pubitemid 47185833)
32. Gibbs KD Jr, Jager A, Crespo O, Goltsev Y, Trejo A, Richard CE, Nolan GP (2012) Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-Driven AML. Cell Stem Cell 10:210-217
33. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R et al (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19:138-152
34. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, Chiba S, Kurokawa M (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3:207-220
35. Gratacap MP, Guillermet-Guibert J, Martin V, Chicanne G, Tronchere H, Gaits-Iacovoni F, Payrastre B (2011) Regulation and roles of PI3 Kbeta, a major actor in platelet signaling and functions. Adv Enzyme Regul 51:106-116
36. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS et al (2009) High frequency of PTEN, PI3 K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114:647-650
37. Hashimoto K, Matsumura I, Tsujimura T, Kim DK, Ogihara H, Ikeda H, Ueda S, Mizuki M, Sugahara H, Shibayama H et al (2003) Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101:1094-1102 (Pubitemid 36139384)
38. Hazen AL, Smith MJ, Desponts C, Winter O, Moser K, Kerr WG (2009) SHIP is required for a functional hematopoietic stem cell niche. Blood 113:2924-2933
39. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM, Borowski A, Jirik F, Krystal G, Humphries RK (1998) Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 12:1610-1620 (Pubitemid 28299513)
40. Helgason CD, Antonchuk J, Bodner C, Humphries RK (2003) Homeostasis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice. Blood 102:3541-3547 (Pubitemid 37409368)
41. Himburg HA, Muramoto GG, Daher P, Meadows SK, Russell JL, Doan P, Chi JT, Salter AB, Lento WE, Reya T et al (2010) Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med 16:475-482
42. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101:3126-3135 (Pubitemid 36858006)
43. Huddleston H, Tan B, Yang FC, White H, Wenning MJ, Orazi A, Yoder MC, Kapur R, Ingram DA (2003) Functional p85alpha gene is required for normal murine fetal erythropoiesis. Blood 102:142-145 (Pubitemid 36759647)
44. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y et al (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11:507-514 (Pubitemid 40685973)
45. Jang YY, Sharkis SJ (2007) A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110:3056-3063 (Pubitemid 350006961)
46. Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, Pearce W, Hirsch E, Wymann MP, Ruckle T, Camps M et al (2007) Inactivation of PI3 Kgamma and PI3 Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 110:2940-2947 (Pubitemid 350006947)
47. Jotta PY, Ganazza MA, Silva A, Viana MB, Da Silva MJ, Zambaldi LJ, Barata JT, Brandalise SR, Yunes JA (2010) Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 24:239-242
48. Juntilla MM, Patil VD, Calamito M, Joshi RP, Birnbaum MJ, Koretzky GA (2010) AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood 115:4030-4038
49. Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94:455-459 (Pubitemid 43289745)
50. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K (2010) Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 115:1406-1415
51. Kiel MJ, Morrison SJ (2008) Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 8:290-301 (Pubitemid 351432804)
52. Kobayashi H, Butler JM, O'Donnell R, Kobayashi M, Ding BS, Bonner B, Chiu VK, Nolan DJ, Shido K, Benjamin L et al (2010) Angiocrine factors from Akt-activated endothelial cells balance selfrenewal and differentiation of haematopoietic stem cells. Nat Cell Biol 12:1046-1056
53. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108:2358-2365 (Pubitemid 44497520)
54. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG et al (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818-822 (Pubitemid 44258912)
55. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G (1998) Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17:3714-3725 (Pubitemid 28327389)
56. Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, Davidson K, Hirose M, Juss J, Oxley D, Chessa TA, et al (2011) PI3 Kbeta plays a critical role in neutrophil activation by immune complexes. Sci Signal 4: ra23
57. Lee EJ, Kim N, Kang KH, Kim JW (2011) Phosphorylation/inactivation of PTEN by Aktindependent PI3 K signaling in retinal pigment epithelium. Biochem Biophys Res Commun 414:384-389
58. Lemmon MA (2008) Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 9:99-111 (Pubitemid 351158910)
59. Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G 2nd, Abboud CN (2007) Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 31:1553-1563 (Pubitemid 47632788)
60. Liu TC, Lin PM, Chang JG, Lee JP, Chen TP, Lin SF (2000) Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 63:170-175
61. Lo TC, Barnhill LM, Kim Y, Nakae EA, Yu AL, Diccianni MB (2009) Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk Res 33:1562-1566
62. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K, Hanamura I, Miura K, Iida S, Ueda R et al (2003) Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 17:1-8 (Pubitemid 36175881)
63. Machado-Neto JA, Traina F, Lazarini M, Campos Pde M, Pagnano KB, Lorand-Metze I, Costa FF, Saad ST (2011) Screening for hotspot mutations in PI3 K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. Clinics (Sao Paulo) 66:793-799
64. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18:1333-1349
65. Martin V, Guillermet-Guibert J, Chicanne G, Cabou C, Jandrot-Perrus M, Plantavid M, Vanhaesebroeck B, Payrastre B, Gratacap MP (2010) Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 115:2008-2013
66. McCrea HJ, De Camilli P (2009) Mutations in phosphoinositide metabolizing enzymes and human disease. Physiology (Bethesda) 24:8-16
67. McLornan DP, McMullin MF, Johnston P, Longley DB (2007) Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opin Drug Metab Toxicol 3:363-377 (Pubitemid 47316029)
68. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS, Ko YW (2003) Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17:995-997 (Pubitemid 36626336)
69. Mise J, Dembitz V, Banfic H, Visnjic D (2011) Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells. Pathol Oncol Res 17:645-656
70. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S, Matsuoka S, Miyamoto T, Ito K, Ohmura M et al (2007) Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1:101-112 (Pubitemid 46865800)
71. Moody JL, Xu L, Helgason CD, Jirik FR (2004) Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten ± SHIP-/-mice: a novel model of myelodysplasia. Blood 103:4503-4510 (Pubitemid 38745976)
72. Nakao T, Geddis AE, Fox NE, Kaushansky K (2008) PI3 K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27 (Kip1). Cell Cycle 7:257-266 (Pubitemid 351366527)
73. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA (2009) Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113:5549-5557
74. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T, Piccaluga PP, Martinelli G, Cocco L, Martelli AM (2006) Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 20:230-238 (Pubitemid 43148660)
75. Papakonstanti EA, Zwaenepoel O, Bilancio A, Burns E, Nock GE, Houseman B, Shokat K, Ridley AJ, Vanhaesebroeck B (2008) Distinct roles of class IA PI3 K isoforms in primary and immortalised macrophages. J Cell Sci 121:4124-4133
76. Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguie F et al (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22:1698-1706
77. Payrastre B, Missy K, Giuriato S, Bodin S, Plantavid M, Gratacap M (2001) Phosphoinositides: key players in cell signalling, in time and space. Cell Signal 13:377-387 (Pubitemid 32510988)
78. Payrastre B, Gaits-Iacovoni F, Sansonetti P, Tronchere H (2012) Phosphoinositides and cellular pathogens. Subcell Biochem 59:363-388
79. Pendaries C, Tronchere H, Plantavid M, Payrastre B (2003) Phosphoinositide signaling disorders in human diseases. FEBS Lett 546:25-31 (Pubitemid 36782278)
80. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105:2527-2534 (Pubitemid 40387055)
81. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532 (Pubitemid 24264918)
82. Rommel C, Camps M, Ji H (2007) PI3 K delta and PI3 K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7:191-201
83. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM (2011) Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 25:1711-1717
84. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, Swider CR, Strzelecki AC, Cavelier C, Recher C et al (2011) Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 121:384-395
85. Sasaki J, Kofuji S, Itoh R, Momiyama T, Takayama K, Murakami H, Chida S, Tsuya Y, Takasuga S, Eguchi S (2010) The PtdIns (3, 4) P (2) phosphatase INPP4A is a suppressor of excitotoxic neuronal death. Nature 465:497-501
86. Scadden DT (2006) The stem-cell niche as an entity of action. Nature 441:1075-1079 (Pubitemid 43990719)
87. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT (2008) PTEN posttranslational inactivation and hyperactivation of the PI3 K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118:3762-3774
88. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N et al (2005) Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106:1063-1066 (Pubitemid 41076455)
89. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM et al (2011) AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146:697-708
90. Tabellini G, Cappellini A, Tazzari PL, Fala F, Billi AM, Manzoli L, Cocco L, Martelli AM (2005) Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 202:623-634 (Pubitemid 40041333)
91. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O et al (2007) Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110:1025-1028 (Pubitemid 47267443)
92. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C et al (2008) Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111:379-382
93. Tamura N, Hazeki K, Okazaki N, Kametani Y, Murakami H, Takaba Y, Ishikawa Y, Nigorikawa K, Hazeki O (2009) Specific role of phosphoinositide 3-kinase p110alpha in the regulation of phagocytosis and pinocytosis in macrophages. Biochem J 423:99-108
94. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM (2007a) The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21:886-896 (Pubitemid 46672063)
95. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA et al (2007b) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21:427-438
96. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD (2008) PI3 K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol 140:344-347
97. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C et al (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128:325-339 (Pubitemid 46137992)
98. Tuveson DA, Carter RH, Soltoff SP, Fearon DT (1993) CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260:986-989 (Pubitemid 23209973)
99. Vanhaesebroeck B, Jones GE, Allen WE, Zicha D, Hooshmand-Rad R, Sawyer C, Wells C, Waterfield MD, Ridley AJ (1999) Distinct PI (3) Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol 1:69-71 (Pubitemid 129495013)
100. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC (2005) Signalling by PI3 K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30:194-204 (Pubitemid 40463309)
101. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3 K signalling. Nat Rev Mol Cell Biol 11:329-341
102. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML (2003) Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102:1466-1473 (Pubitemid 36988058)
103. Watts KL, Delaney C, Humphries RK, Bernstein ID, Kiem HP (2010) Combination of HOXB4 and Delta-1 ligand improves expansion of cord blood cells. Blood 116:5859-5866
104. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102:972-980 (Pubitemid 36917792)
105. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475-482 (Pubitemid 44050144)
106. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M et al (2011) Evi1 represses PTEN expression and activates PI3 K/AKT/mTOR via interactions with polycomb proteins. Blood 117:3617-3628
107. Zanella F, Rosado A, Garcia B, Carnero A, Link W (2008) Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chem Bio Chem 9:2229-2237
108. Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, Stoiber D, Weisz E, Schmid JA et al (2008) Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood 112:4655-4664
109. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M (2006) Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5:3113-3121 (Pubitemid 46092053)
110. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ et al (2003) Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425:836-841 (Pubitemid 37351467)
111. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM et al (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441:518-522 (Pubitemid 44050154)
112. Zhou M, Gu L, Findley HW, Jiang R, Woods WG (2003) PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 63:6357-6362 (Pubitemid 37255184)